Beximco Pharmaceuticals (BXP) Stock Overview
Manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for BXP from our risk checks.
BXP Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Beximco Pharmaceuticals PLC. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ৳0.42 |
| 52 Week High | ৳0.52 |
| 52 Week Low | ৳0.32 |
| Beta | 0.062 |
| 1 Month Change | 0% |
| 3 Month Change | 4.94% |
| 1 Year Change | 10.39% |
| 3 Year Change | -6.59% |
| 5 Year Change | -50.87% |
| Change since IPO | 111.05% |
Recent News & Updates
Recent updates
Shareholder Returns
| BXP | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | 4.6% | 1.9% |
| 1Y | 10.4% | 32.8% | 23.2% |
Return vs Industry: BXP underperformed the UK Pharmaceuticals industry which returned 31.8% over the past year.
Return vs Market: BXP underperformed the UK Market which returned 21.1% over the past year.
Price Volatility
| BXP volatility | |
|---|---|
| BXP Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 4.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine BXP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 1,122 | Iqbal Ahmed | www.beximcopharma.com |
Beximco Pharmaceuticals PLC. manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies.
Beximco Pharmaceuticals PLC. Fundamentals Summary
| BXP fundamental statistics | |
|---|---|
| Market cap | UK£336.91m |
| Earnings (TTM) | UK£38.32m |
| Revenue (TTM) | UK£279.53m |
Is BXP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BXP income statement (TTM) | |
|---|---|
| Revenue | ৳46.34b |
| Cost of Revenue | ৳25.76b |
| Gross Profit | ৳20.58b |
| Other Expenses | ৳14.23b |
| Earnings | ৳6.35b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 14.24 |
| Gross Margin | 44.42% |
| Net Profit Margin | 13.71% |
| Debt/Equity Ratio | 10.8% |
How did BXP perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/18 04:02 |
| End of Day Share Price | 2025/12/31 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Beximco Pharmaceuticals PLC. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| S M Toufique Imran | BRAC EPL Stock Brokerage Ltd |
| Asif Khan | EDGE Research & Consulting |
| Lorenza Castellon | Equity Development Limited |